CI-994

• Catalog No.: C0621
• CAS Number: 112522-64-2
• M. F.: C15H15N3O2
• M. W.: 269.2985
• Purity: ≥98% (HPLC)
• Storage: under inert gas

SYNONYMS

• IUPAC name: N-(2-aminophenyl)-4-acetamidobenzamide
• IUPAC Traditional name: tacedinaline
• Synonyms: Tacedinaline; 4-Acetylamino-N-(2′-aminophenyl)benzamide; Acetyldinaline

DATABASE IDS

• MDL Number: MFCD00866266
• CAS Number: 112522-64-2

PROPERTIES

• German water hazard class: 3
• GHS Signal Word: Warning
• GHS Hazard statements: H319
• European Hazard Symbols: Irritant (Xi)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• GHS Precautionary statements: P305 + P351 + P338
• Risk Statements: 36
• RTECS: CU8702023
• Safety Statements: 26
• Storage Condition: under inert gas
• Storage Temperature: room temp
• Empirical Formula (Hill Notation): C15H15N3O2
• Purity: ≥98% (HPLC)
• Apperance: off-white powder
• Solubility: DMSO: >10 mg/mL

DETAILS

Description (English)

Biochem/physiol Actions
CI-994 is the acetylated derivative form of the original compound Dinaline (PD 104 208). It is an oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. It is used for combination therapy for selected tumors including non-small cell lung, pancreatic, breast, and colorectal cancers. It acts as a histone deacetylase inhibitor. CI-994 blocks cells in the G1-S phase of the cell cycle. The 16 kDa phosphoprotein is confined to the nuclear compartment. Loss of the 16-kDa nuclear phosphoprotein appears to be a direct effect of CI-994 treatment and that the inhibition of this phosphoprotein may play a critical role in the mechanism of action of CI-994.

Description (简体中文)

Biochem/physiol Actions
CI-994 is the acetylated derivative form of the original compound Dinaline (PD 104 208). It is an oral cytostatic drug with impressive differential activity against leukemic cells & normal stem-cells. It is used for combination therapy for selected tumors including non-small cell lung, pancreatic, breast, and colorectal cancers. It acts as a histone deacetylase inhibitor. CI-994 blocks cells in the G1-S phase of the cell cycle. The 16 kDa phosphoprotein is confined to the nuclear compartment. Loss of the 16-kDa nuclear phosphoprotein appears to be a direct effect of CI-994 treatment and that the inhibition of this phosphoprotein may play a critical role in the mechanism of action of CI-994.